Getting Lost in the Thicket: AbbVie Wields Its Expansive Humira® Patent Portfolio Against Alvotech’s Adalimumab Biosimilar
![Rothwell Fig logo 1 | International Network of Boutique and Independent Law Firms](https://www.inblf.com/wp-content/uploads/2020/09/Rothwell-Fig-logo-1.png)
![Rothwell Fig logo 1 | International Network of Boutique and Independent Law Firms](https://www.inblf.com/wp-content/uploads/2020/09/Rothwell-Fig-logo-1.png)
Author: Andrew J. StoraskaPublished: June 24, 2021In the most recent of a series of litigations by AbbVie against manufacturers seeking to market biosimilar versions of Humira®, the world’s most profitable drug, AbbVie initiated an action against Alvotech in the district court for the Northern District of Illinois on April 27, 2021,
Read More